NCT05604248

Brief Summary

Vitamin A deficiency (VAD) is still a serious public health problem in most developing countries. Several strategies are used to prevent and address the consequences of this deficiency and to reduce its prevalence, particularly in Africa. In Senegal, the prevalence of VAD, although low among women of reproductive age, is quite worrying among children under 5 years old. In 2009, the fortification of refined oil with vitamin A was made mandatory in addition to the strategies already in place. The study of the impact of these strategies on the vitamin A status of women and children, showed relatively stable prevalences between 2010 and 2018. However, this study used plasma retinol concentration as an indicator. It is known that evaluation of vitamin A status is relatively insensitive when based on changes in plasma retinol concentrations, which are homeostatically controlled and negatively affected by subclinical infections. Incremental studies in the Dakar region using the modified relative dose response (MRDR) test in children under 2 years of age have indicated adequate vitamin A stores and a low prevalence of vitamin A deficiency in these children. The various strategies to prevent and control vitamin A deficiency have reportedly improved and even increased vitamin A stores in women and children, particularly in the Dakar region. Indeed, the latter benefit from substantial intakes of preformed retinol through the fortification program, and the majority of children under 2 years of age are breastfed. The aim of this study is to use a more sensitive method than plasma retinol, the retinol isotope dilution (RID) test, to assess the actual status of subjects following these different strategies and to better orient the policies implemented in Senegal.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
56

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 27, 2022

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 3, 2022

Completed
5 months until next milestone

Study Start

First participant enrolled

April 1, 2023

Completed
7 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 8, 2023

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 8, 2023

Completed
Last Updated

November 10, 2022

Status Verified

October 1, 2022

Enrollment Period

7 days

First QC Date

October 27, 2022

Last Update Submit

November 8, 2022

Conditions

Keywords

Vitamin A statusRetinol isotope dilution techniquecompartmental modelingWonder women13C2-Retinyl acetateSenegal

Outcome Measures

Primary Outcomes (1)

  • Vitamin A status

    Total body store vitamin A (µmol)

    Within the coming 2 years

Study Arms (1)

Lactating mother-infant pair

OTHER

8 arms of 7 lactating women for a total of 56 women following a study design integrating a model-based compartmental analysis with the Retinol Isotope Dilution (RID) technique using a "Wonder women" approach. For infants, the RID test will start at day 14. After the baseline blood, they will receive 1.0 μmol 13C2-retinyl acetate and will have a second blood sample at day 28.

Other: Intervention

Interventions

Mother : 2.0 μmol 13C2 -retinyl acetate diluted in soybean oil Children : 1.0 μmol 13C2 -retinyl acetate diluted in soybean oil

Also known as: Stable isotope
Lactating mother-infant pair

Eligibility Criteria

Age9 Months - 45 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • For mothers: Willing to participate in the study and to give 4 blood and 4 milk samples during the whole duration of the study, Being aged 18-45 years, Not planning to travel during the study duration
  • For children: Being aged 9-18 months, Being breastfed, Mother willing to authorize 2 bloods, Do not receive vitamin A supplements during the study

You may not qualify if:

  • For mothers: Being pregnant, Consuming vitamin A and/or effector supplements, Smoke or drink alcohol during the study period
  • For children: Have received a vitamin A supplement in the two months prior to the study
  • All: Had fever or any obviously known or clinical diagnosed disease, malaria positive, severe anemia, severe acute malnutrition or severe obesity, being hemophiliac

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Universite Cheikh Anta Diop

Dakar, 10700, Senegal

Location

MeSH Terms

Interventions

MethodsIsotope Labeling

Intervention Hierarchy (Ancestors)

Investigative Techniques

Study Officials

  • Pernille Kaestel, PhD

    International Atomic Energy Agency

    STUDY DIRECTOR

Central Study Contacts

Nicole Idohou-Dossou,, Pr

CONTACT

Adama Diouf, Pr

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 27, 2022

First Posted

November 3, 2022

Study Start

April 1, 2023

Primary Completion

April 8, 2023

Study Completion

July 8, 2023

Last Updated

November 10, 2022

Record last verified: 2022-10

Data Sharing

IPD Sharing
Will not share

Locations